key: cord-0973924-mvi7aihx
authors: Xia, Hongjie; Cao, Zengguo; Xie, Xuping; Zhang, Xianwen; Yun-Chung Chen, John; Wang, Hualei; Menachery, Vineet D.; Rajsbaum, Ricardo; Shi, Pei-Yong
title: Evasion of type-I interferon by SARS-CoV-2
date: 2020-09-19
journal: Cell Rep
DOI: 10.1016/j.celrep.2020.108234
sha: 054c380f71f57f855d2cc13b84bdbae9782ad4d3
doc_id: 973924
cord_uid: mvi7aihx

The coronavirus disease 2019 (COVID-19) is determined by SARS-CoV-2 replication and host immune response, but studies evaluating viral evasion of immune response are lacking. Here we employed unbiased screening to identify SARS-CoV-2 proteins that antagonize type-I interferon (IFN-I) response. Three proteins were found to antagonize IFN-I production via distinct mechanisms: nsp6 binds TBK1 to suppress IRF3 phosphorylation; nsp13 binds and blocks TBK1 phosphorylation; and ORF6 binds importin KPNA2 to inhibit IRF3 nuclear translocation. Two sets of viral proteins were identified to antagonize IFN-I signaling through blocking STAT1/STAT2 phosphorylation or nuclear translocation. Remarkably, SARS-CoV-2 nsp1 and nsp6 suppressed IFN-I signaling more efficiently than SARS-CoV and MERS-CoV. Thus, when treated with IFN-I, a SARS-CoV2 replicon replicated to a higher level than chimeric replicons containing nsp1 or nsp6 from SARS-CoV or MERS-CoV. Altogether, the study has provided insights on SARS-CoV-2 evasion of IFN-I response and its potential impact on viral transmission and pathogenesis.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, 17 China in December 2019, and has led to a global pandemic of coronavirus disease 2019 18 (COVID-19) (Zhou et al., 2020; Zhu et al., 2020) . As of July 4, 2020, there have been over 11 19 million confirmed cases and over 525,000 deaths in six months (https://coronavirus.jhu.edu/). 20

Typical clinical symptoms of SARS-CoV-2 infection range from mild to severe respiratory illness, 21 including fever, dry cough, breathing difficulties, acute respiratory distress, which may lead to 22 long-term reduction in lung function and death (Wu and McGoogan, 2020) . Before SARS-CoV-2, 23 two other highly pathogenic coronaviruses emerged in the past two decades, including severe 24 acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV) 25 J o u r n a l P r e -p r o o f (Assiri et al., 2013; Huang et al., 2020) . In addition, four endemic human coronaviruses (i.e., 26 OC43, 229E, NL63, and HKU1) cause common cold respiratory diseases. SARS-CoV-2 is an 27 enveloped β-coronavirus from the Coronaviridae family. It has a positive-sense, single-stranded 28 RNA (Fig. 1a) J o u r n a l P r e -p r o o f either nsp6 or nsp13. At 24 hpt, cells were analyzed for TBK1 phosphorylation. Nsp13, but not 128 nsp6, inhibited TBK1 phosphorylation in a dose-dependent manner (Fig. 2b ). In agreement with 129 the results from Fig. 2a , both nsp6 and nsp13 suppressed IRF3 phosphorylation (Fig. 2b) . 130

Further, we examined if nsp6 or nsp13 interacts with TBK1. Co-immunoprecipitation showed 131 that both nsp6 and nsp13 could pull down TBK1 (Fig. 2c) . Collectively, the results indicate that (i) 132 nsp6 binds to TBK1 without affecting TBK1 phosphorylation, but the nsp6/TBK1 interaction 133 decreases IRF3 phosphorylation, which leads to reduced IFN-β production; (ii) nsp13 binds and 134 inhibits TBK1 phosphorylation, resulting in decreased IRF3 activation and IFN-β production (Fig.  135 2f). 136 ORF6 inhibits nuclear translocation of IRF3. The results from Fig. 1c suggest that 137 ORF6 inhibits IFN-β production through IRF3 or a component downstream of IRF3. Thus, we 138 examined the effect of ORF6 on IRF3 nuclear translocation. Upon poly(I:C) treatment, IRF3 139 translocated to the cell nucleus in the absence of ORF6, whereas the expression of ORF6 140 blocked its nuclear translocation (Fig. 2d) . Karyopherin alpha 1 to 6 (KPNA1 to 6) are importing 141 factors for nuclear translocation of cargos, including IRF3, IRF7, and STAT1 (Chook and Blobel, 142 2001 ). Co-immunoprecipitation showed that ORF6 selectively interacted with KPNA2, but not 143 the other KPNAs (Fig. 2e) , suggesting that ORF6 inhibits IFN-β production by binding to KPNA2 144 to block IRF3 nuclear translocation (Fig. 2f) . 145

Although SARS-CoV-2 was 146 reported to be highly sensitive to IFN-I inhibition (Xie et al., 2020a) , it remains to be determined 147 which viral proteins antagonize IFN-I signaling. We screened SARS-CoV-2 proteins in an IFN-I 148 signaling assay using a plasmid (pISRE-luc) that contains a luciferase reporter driven by an 149 IFN-stimulated response element (ISRE) promoter. HEK293T cells were co-transfected with 150 three plasmids: (i) a reporter plasmid pISRE-luc, (ii) a plasmid encoding an individual SARS-151

CoV-2 protein, and (iii) a plasmid phRluc-TK for normalizing transfection efficiency. An empty 152 J o u r n a l P r e -p r o o f plasmid or an EGFP-expressing plasmid was included as negative controls. At 24 hpt, cells 153

were treated with IFN-α for 8 h and assayed for luciferase signals to quantify the activation of 154 ISRE. Ten proteins significantly suppressed IFN-α signaling, including nsp1, nsp6, nsp7, nsp13, 155 nsp14, ORF3a, M, ORF6, ORF7a, and ORF7b (Fig. 3a) . 156

We examined viral suppression of STAT1 and STAT2 phosphorylation. We analyzed 157 nsp1, nsp6, nsp13, ORF3a, M, ORF6, ORF7a, and ORF7b because these proteins 158 suppressed >40% of ISRE promoter activity (Fig. 3a) . HEK293T cells were transfected with a 159 plasmid encoding each respective SARS-CoV-2 protein, treated with IFN-α, and then analyzed 160 for STAT1 and STAT2 phosphorylation (Fig. 3b) Other than ORF6, we also tested nsp1, nsp6, nsp13, ORF3a, M, ORF7a, and ORF7b for 179 For IFN-I signaling, we compared the inhibition by nsp1, nsp6, nap13, ORF6, ORF7a, 193 and ORF7b among SARS-CoV-2, SARS-CoV, and MERS-CoV (Fig. 4b) . These proteins were 194 chosen because they suppressed >50% of the IFN-α signaling in SARS-CoV-2 (Fig. 3a) . 195 Compared to nsp1 and nsp6 of SARS-CoV-2, those of SARS-CoV and MERS-CoV were 196 significantly weaker in inhibiting IFN-α signaling, whereas comparable inhibition was observed 197 for the other viral proteins among the three viruses (Fig. 4b) . Notably, SARS-CoV nsp6 did not 198 suppress IFN-I signaling (Fig. 4b) . To confirm these results, we compared the effects of nsp1 199 and nsp6 from the three viruses on STAT1 and STAT2 phosphorylation ( with the finding that the former inhibited IFN-I signaling more efficiently than the latter (Fig. 4b) . CoV nsp6 were more sensitive to IFN-α inhibition. Without IFN-α treatment, the chimeric 304 replicons replicated to the wild-type SARS-CoV-2 replicon level; however, chimeric replicon 305 containing MERS-CoV nsp1 was lethal (Fig. 6b and c) . The replication capability of chimeric 306

replicons correlated with the relative degree of protein sequence homology of nsp1 or nsp6 307 among the three viruses (Fig. S4) . RIG-I-induced IFN-β promoter luciferase assay was performed by co-transfection of HEK293T 426 cells as described in Fig. 1. (b) ISRE promoter luciferase assay. HEK293T cells were co-427 transfected with pISRE-luc luciferase reporter plasmid, phRluc-TK control plasmid, and viral 428 protein expressing plasmid. At 24 hpt, the cells were treated with 1,000 U/ml IFN-α and assayed 429 for luciferase activities after 8 h. Error bars represent mean ± SD from three independent 430 experiments. Statistical significance was determined by comparing with SARS-CoV-2 and two-431 way ANOVA with Dunnett correction, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (c) 432

Western blot of phosphorylated STAT1 and STAT2. HEK293T cells were transfected with viral 433 protein expressing plasmid and then treated with 1,000 U/ml IFN-α at 24 hpt for 30 min. 434

Western blot was performed to analyze the cell lysates using anti-phosphorylated STAT1 (Y701) 435 and STAT2 (Y690), and anti-total STAT1 and STAT2 antibodies. Protein band intensities were 436 quantitated by Image lab software. 437 CoV-2 and two-way ANOVA with Dunnett correction, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 461 were washed three times with phosphate-buffered saline (PBS), then fixed in PBS containing 4% 556 paraformaldehyde (Sigma-Aldrich) at room temperature for 20 min, and permeabilized with 1% 557 Triton X-100 (Sigma-Aldrich) in PBS at room temperature for 20 min. After three washes, cells 558

were treated with PBS containing 2% FBS for blocking at room temperature for 1 h, followed by 559 conjugated with Alexa Fluor 488 or 568). Cells were washed for three times, and counterstained 561 with 4',6-diamidino-2-phenylindole (DAPI, Vector Laboratories, Burlingame, CA). Images were 562 obtained by using Eclipse Ti2 inverted fluorescence microscope (Nikon). were obtained by digesting the corresponding plasmids with enzyme BsaI as previously 573 described (Xie et al., 2020a ). An Esp3I restriction cleavage site was engineered at nucleotide 574 21,213 in F5A and F6A was constructed by overlap PCR. Therefore, both of F5A and F6A could 575 be obtained by Esp3I digestion. To assemble the SARS-CoV-2 transient luciferase replicon 576 DNA, equimolar amounts of six contiguous cDNA fragments (totally 5 µg) were in vitro ligated in 577 a 100-µl reaction with T4 ligase (NEB, Ipswich, MA). The ligated production was identified by 578 agarose gel, followed by purification using phenol/chloroform, isopropanol precipitation, and 579 resuspended in nuclease-free water. 580 SARS-CoV-2 luciferase replicon RNA was in vitro synthesized using mMESSAGE 581 mMACHINE T7 Transcription Kit (ThermoFisher Scientific) according to the manufacturer's 582 instruction. After incubation 6 h at 37°C, DNA template (2 µg) was removed by DNase, the RNA 583 was purified through phenol/chloroform extraction and isopropanol precipitation. The N gene 584 mRNA was obtained through T7 RNA in vitro transcription as previously described ( 

Dysregulation of type I interferon responses in 616 COVID-19

Severe acute 618 respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane 619 vesicles

Epidemiological, 622 demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome 623 coronavirus disease from Saudi Arabia: a descriptive study. The Lancet. Infectious diseases

Transcriptional regulation by STAT1 626 and STAT2 in the interferon JAK-STAT pathway

Essential role for the dsRNA-dependent protein kinase PKR in innate 630 immunity to viral infection

The Matrix Protein of Nipah Virus Targets the E3-Ubiquitin 633

Ligase TRIM6 to Inhibit the IKKepsilon Kinase-Mediated Type-I IFN Antiviral Response

USP22 promotes IRF3 nuclear translocation and antiviral responses by deubiquitinating 637 the importin protein KPNA2

Pathogenic human coronavirus infections: 640 causes and consequences of cytokine storm and immunopathology. Seminars in 641 immunopathology

Karyopherins and nuclear import. Current opinion in 643 structural biology

Comparative replication and immune activation profiles of SARS-CoV-2 and 646 SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-647 19. Clinical infectious diseases : an official publication of the Infectious Diseases Society of 648 America

ORF7-encoded accessory protein 7a of feline infectious peritonitis virus 651 as a counteragent against IFN-alpha-induced antiviral response. The Journal of general virology

IKKepsilon and TBK1 are essential components of the IRF3 655 signaling pathway

Severe acute 657 respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic 658 domain regulate antagonism of IRF3 and NF-kappaB signaling

Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by 662 sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. 663

Envelope protein ubiquitination drives entry 666 and pathogenesis of Zika virus

The Severe 668

Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by 669 Interfering with TRIM25-Mediated RIG-I Ubiquitination

SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage 673 of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage

Clinical features of patients infected with 2019 novel coronavirus in

A two-679 pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein. Nature 680 structural & molecular biology

Severe acute respiratory syndrome coronavirus nsp1 protein suppresses 683 host gene expression by promoting host mRNA degradation

Differential roles of MDA5 and RIG-I helicases in the 687 recognition of RNA viruses

Interaction of SARS and MERS Coronaviruses with 689 the Antiviral Interferon Response

Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and 693 nucleocapsid proteins function as interferon antagonists

SARS-CoV-2-specific T cell immunity in cases of COVID-697 19 and SARS, and uninfected controls

Activation and evasion of type I interferon responses by SARS-CoV-2

Stats: transcriptional control and biological impact. 702 Nature reviews

Coronavirus infections and immune responses

Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces 708 IRF3 activation

SARS-CoV-2 is sensitive to type I interferon pretreatment. bioRxiv : the preprint server for 711 biology

Small self-RNA generated by 713

RNase L amplifies antiviral innate immunity

Antiviral activities 716 of type I interferons to SARS-CoV-2 infection

Intracellular pattern recognition receptors in the 719 host response

Severe acute respiratory syndrome coronavirus nsp1 suppresses host gene 722 expression, including that of type I interferon, in infected cells

The papain-like protease determines a 726 virulence trait that varies among members of the SARS-coronavirus species

Interaction between the HCV NS3 protein and the host TBK1 protein leads to 730 inhibition of cellular antiviral responses

Type I and Type III Interferons -Induction, Signaling, Evasion, 732 and Application to Combat COVID-19

Remdesivir potently inhibits SARS-736

CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA 737 polymerase in mice. bioRxiv : the preprint server for biology

Type 1 739 interferons as a potential treatment against COVID-19

Antiviral actions of interferons

Interferon-stimulated genes: a 744 complex web of host defenses

Corrigendum: A diverse range of gene products are effectors of the type I 748 interferon antiviral response

Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by 751 impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex

SARS coronavirus pathogenesis: host innate immune 754 responses and viral antagonism of interferon

Chloroquine is a potent inhibitor of SARS coronavirus infection 758 and spread

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus 761 (2019-nCoV) in vitro

Characteristics of and Important Lessons From the 763

COVID-19) Outbreak in China: Summary of a Report of 72314 764 Cases From the Chinese Center for Disease Control and Prevention

An evolutionary NS1 mutation enhances Zika 768 virus evasion of host interferon induction

An Infectious cDNA Clone of SARS-CoV-2. Cell 772 Host Microbe

A nanoluciferase SARS-CoV-2 for rapid 775 neutralization testing and screening of anti-infective drugs for COVID-19. bioRxiv : the preprint 776 server for biology

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent 779 interferon antagonists. Emerging microbes & infections

A pneumonia outbreak associated with a new coronavirus of probable bat 783 origin

A Novel Coronavirus from Patients with Pneumonia in China

This paper N/A pXJ-SARS-CoV-2-nsp2 This paper N/A pXJ-SARS-CoV-2-nsp3 This paper N/A pXJ-SARS-CoV-2-nsp4 This paper N/A pXJ-SARS-CoV-2-nsp5 This paper N/A pXJ-SARS-CoV-2-nsp6 This paper N/A pXJ-SARS-CoV-2-nsp7This paper N/A pXJ-SARS-CoV-2-nsp8This paper N/A pXJ-SARS-CoV-2-nsp9This paper N/A pXJ-SARS-CoV-2-nsp10This paper N/A pXJ-SARS-CoV-2-nsp11-EGFP This paper N/A pXJ-SARS-CoV-2-nsp12This Laboratories, Logan, UT) and 1% penicillin/streptomycin (Invitrogen) at 37°C with 5% CO 2 . 487 A549 cells were grown in minimum essential medium, supplemented with 1% nonessential 488 amino acids, 1% sodium pyruvate, 10% FBS, 1% penicillin/streptomycin at 37°C with 5% CO 2 . 489All culture medium and antibiotics were purchased from ThermoFisher Scientific (Waltham, MA). 490All cell lines were tested negative for mycoplasma. groups were performed using one-way ANOVA or two-way ANOVA, *P < 0.05, **P < 0.01, ***P 610 < 0.001, ****P < 0.0001. The 50% effective concentration (EC 50 ) was determined by nonlinear 611